Fig. 1
From: EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers
Flowchart of the study design. a Consolidation of the discovery cohort from seven published studies. Samples from the first four studies (Rizvi et al. [22], Snyder et al. [23], Van Allen et al. [24], Miao et al. [25]) have been curated and filtered by Miao et al. *Hellmann et al. cohort did not include OS data and Hugo et al. cohort did not include PFS data. b Consolidation of the validation cohort and the non-ICI-treated cohort from Samstein et al. c Consolidation of TCGA pan-cancer dataset. OS, overall survival; TMB, tumor mutation burden; CNA, copy number alteration; NAL, neoantigen analysis; GDC, Genomic Data Commons; MSKCC, Memorial Sloan Kettering Cancer Center